Egetis Therapeutics
Egetis Therapeutics is a rare disease pharmaceutical company developing and commercializing treatments for serious conditions with significant unmet medical need. Its lead product, Emcitate® (tiratricol), is the first approved treatment for MCT8 deficiency in both the United States and European Union, addressing a rare, life-limiting disorder that disrupts thyroid hormone transport.
- Drug Discovery & Therapeutics
- Healthcare Technology
- Biotechnology
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Rare diseases affect an estimated 300 million people worldwide, yet most rare diseases still lack approved treatment options. For patients and families living with serious rare conditions such as MCT8 deficiency, this means years of uncertainty, limited treatment options, and significant daily challenges with no current therapeutic alternatives available.
Solution
Egetis Therapeutics develops innovative therapies for rare diseases with significant unmet medical need, working closely with patients, caregivers, healthcare professionals, and advocacy organizations to understand the challenges faced by the communities they serve. The company's lead product, Emcitate® (tiratricol), is the first approved treatment for MCT8 deficiency in the United States and European Union, a rare, life-limiting disorder that disrupts thyroid hormone transport and leads to severe neurodevelopmental impairment and systemic complications. Egetis focuses on late-stage development, regulatory approval, market access, and commercialization to ensure innovative treatments reach patients who need them most. The company's activities span the full development-to-delivery pathway, combining scientific expertise, clinical development capabilities, and a patient-centered approach to bring meaningful therapies to people with few or no treatment options.
Target Audience
Primary customers are patients living with rare thyroid hormone disorders such as MCT8 deficiency and RTH-beta, along with the healthcare professionals, caregivers, and advocacy organizations that support them.
Features
- Emcitate® (tiratricol) is the first FDA- and EMA-approved treatment for MCT8 deficiency, a rare thyroid hormone transport disorder
- Pipeline includes development programs for Resistance to Thyroid Hormone Beta (RTH-beta), expanding beyond the lead MCT8 deficiency indication
- Clinical development capabilities spanning late-stage trials, regulatory approval, and market access
- Patient-centered research approach that collaborates with patients, caregivers, healthcare professionals, and advocacy organizations
- Educational resources and support programs for patients, caregivers, and healthcare professionals managing MCT8 deficiency
- Dedicated healthcare professional portal providing medical information, clinical trial access, and managed access programs